Genedrive PLC (GB:GDR)
LSE:GDR
Want to see GB:GDR full AI Analyst Report?
GDR Stock Chart & Stats
0.88 p
0.03 p(1.30%)
At close: 4:00 PM EST
0.88 p
0.03 p(1.30%)
Day’s Range― - ―
52-Week Range0.19 p - 1.85 p
Previous CloseN/A
Volume280.42K
Average Volume (3M)49.58M
Market Cap
£14.85M
Enterprise Value5.84M
Total Cash (Recent Filing)£387.00K
Total Debt (Recent Filing)£500.00K
Price to Earnings (P/E)―
Beta-1.05
Next Earnings
Nov 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,605,568,200
10 Day Avg. Volume14,118,826
30 Day Avg. Volume49,583,488
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.48
Price to Sales (P/S)10.31
P/FCF Ratio-1.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables RevenueGenedrive's business includes recurring revenue from single-use test cartridges and assays tied to installed instruments. This consumables model supports predictable, repeatable revenue and margin leverage as installed base grows, improving long-term unit economics if instrument placements scale.
Portable Point-of-care PlatformThe Genedrive portable PCR platform targets decentralized, point-of-care diagnostics where speed and on-site genetic results matter. Product-led differentiation versus central lab incumbents can create durable demand in clinical settings and drive long-term adoption across fragmented end-markets.
Low LeverageZero reported debt in 2025 reduces immediate refinancing and interest risks, preserving financial flexibility while operations scale. Low leverage gives management optionality to invest in commercialization or R&D without large near-term debt service burdens, important over the next several months.
Bears Say
Sustained Cash BurnOperating and free cash flow around -£5.1m in 2025 show continued cash burn. Over a multi-month horizon this dependence on external funding constrains runway, limits self-funded commercialization, and elevates dilution risk unless cash generation reverses.
Persistently Negative ProfitabilityDespite top-line acceleration, operating losses near -£5m indicate the cost base outstrips current scale. If margins don't improve through higher volumes or lower unit costs, extended unprofitability will pressure cash reserves and force difficult trade-offs in pricing, R&D, or go-to-market spend.
Eroding Equity BaseShareholders' equity compression to ~£1.4m reduces the balance-sheet cushion and heightens the likelihood of further dilution or urgent capital raises. Over the coming months this weak equity buffer limits resilience to setbacks and reduces leverage when negotiating financing or partnerships.
Genedrive News
GDR FAQ
What was Genedrive PLC’s price range in the past 12 months?
Genedrive PLC lowest share price was 0.19 p and its highest was 1.85 p in the past 12 months.
What is Genedrive PLC’s market cap?
Genedrive PLC’s market cap is £14.85M.
When is Genedrive PLC’s upcoming earnings report date?
Genedrive PLC’s upcoming earnings report date is Nov 26, 2026 which is in 212 days.
How were Genedrive PLC’s earnings last quarter?
Genedrive PLC released its earnings results on Mar 30, 2026. The company reported -0.003 p earnings per share for the quarter, missing the consensus estimate of N/A by -0.003 p.
Is Genedrive PLC overvalued?
According to Wall Street analysts Genedrive PLC’s price is currently Overvalued.
Does Genedrive PLC pay dividends?
Genedrive PLC does not currently pay dividends.
What is Genedrive PLC’s EPS estimate?
Genedrive PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Genedrive PLC have?
Genedrive PLC has 1,605,568,200 shares outstanding.
What happened to Genedrive PLC’s price movement after its last earnings report?
Genedrive PLC reported an EPS of -0.003 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.564%.
Which hedge fund is a major shareholder of Genedrive PLC?
Currently, no hedge funds are holding shares in GB:GDR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Genedrive PLC
genedrive plc, a molecular diagnostics company, engages in developing and commercializing point of need diagnostics platform for infectious diseases, genotyping, pathogen detection, and other indications. The company provides Genedrive, a patented small polymerase chain reaction, which enables rapid nucleic acid amplification and detection from various sample types, including plasma, sputum, and buccal swabs. Its Genedrive platform offers Genedrive HCV ID Kit, a qualitative molecular solution for Hepatitis C Virus testing; Genedrive BioPlex for the rapid determination of military biothreats from pathogens; Genedrive MT-RNR1-ID Kit, a rapid genetic test in an emergency neonatal care setting; and Genedrive Connect app, an android-based mobile app that allows added data management flexibility and results transmission. The company serves biotechnology and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally. It has a collaboration agreement with Beckman Coulter Life Sciences to automate the laboratory PCR testing process for COVID-19. The company was formerly known as Epistem Holdings Plc and changed its name to genedrive plc in July 2016. genedrive plc was founded in 2000 and is headquartered in Manchester, the United Kingdom.
Technical Analysis
EKF Diagnostics Holdings
―
Renalytix
―
Abingdon Health PLC
―
Aptamer Group Plc
―
Oxford Nanopore Technologies PLC
―
Options Prices
Currently, No data available
---